Name:
Lymphocytes differentiation, tolerance and metabolism: basis for immunotherapy
Leader:
- Martin Villalba
Research axis :
- Onco-immunotherapy
- Immunometabolism
- Immunotherapy of inflammatory diseases:autoimmunity
- specific anti-HLA antibodies toxicity,
- endothelial cell activation,
- complement transplantation,
- antibody mediated rejection,
- thrombotic microangiopathy.
Expertise / know-how:
- Generation of in vitro expanded NK cells.
- Studies in Natural cytotoxicity
- Antibody-dependent cell cytotoxicity (ADCC)
- Changes in metabolism and studies on metabolism
- CD8+ and CD4+ T cell characterization
- Mouse models of autoimmunity and immune tolerance
- Glycosylation of antibodies: analysis by mass spectrometry
- In vitro endothelial cells activation
- Complement implication in antibody mediated rejection, endothelial cells activation
- Complement (C5b9, C3, membrane complement regulators ) immunoperoxidase staining
Location:
INSERM Centre: U1183 “Cellules souches, plasticité cellulaire, médecine régénératrice et immunothérapies”. Institute for Regenerative Medicine and Biotherapy (IRMB).
CHU Montpellier Hôpital Saint-Eloi
80, av. Augustin Fliche.
34295 Montpellier Cedex 5 France